Baird Downgrades Regeneron Pharma (REGN) to Neutral

August 3, 2018 5:42 AM EDT Send to a Friend
Baird downgraded Regeneron Pharma (NASDAQ: REGN) from Outperform to Neutral with a price target of $405.00 (from $392.00).Analyst Brian Skorney ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login